• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Therapeutic advances in drug safety

    Therapeutic advances in drug safety

    JournalISSN 2042-0986eISSN 2042-0994中科院 医学 3区

    年发文量

    研究主题

    论文(624)

    排序
    1Comparative Ocular Adverse Events Across Immune Checkpoint and Targeted Therapies in Melanoma: A FAERS-based Pharmacovigilance Analysis
    Hadassah Som-Pimpong BS,Ronny Amamoo PhD, Zane Wilson BS, Aleah J. Brokemond BS,Amadou Gaye PhD,Ravirajsinh N. Jadeja PhD,Pamela M. Martin PhD,Menaka C. Thounaojam PhD

    Background Immune checkpoint inhibitors (ICIs) and targeted therapies like BRAF and MEK inhibitors have improved advanced melanoma outcomes but can cause ocular adverse events that threaten vision if not caught early. While such eye issues have been noted for specific therapies, comparisons across these treatments in real-world populations are limited. Objectives To compare ocular adverse-event phenotypes and associated serious outcomes among ICIs, BRAF inhibitors, and MEK inhibitors in patients with melanoma using a real-world pharmacovigilance database. Design Retrospective pharmacovigilance study utilizing the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Methods FAERS reports from January 2018 to September 2025 analyzed for melanoma-related reports with ocular adverse events. Reports were filtered by indication and deduplicated. Drug exposures grouped into ICIs, BRAF inhibitors, and MEK inhibitors. The main analysis classified reports by the primary suspect drug, with a sensitivity analysis excluding reports with multiple agents. Ocular phenotypes and serious outcomes were assessed using reporting odds ratios (RORs), with p-values adjusted via the Benjamini-Hochberg method. Results A total of 31,482 melanoma-related adverse-event reports were identified, with 2,633 (8.4%) containing at least one ocular adverse event. The primary class-specific cohort included 2,463 reports, and the single-agent cohort included 705 reports. ICIs showed higher reporting of inflammatory and optic nerve events, BRAF inhibitors reported more retinal, choroid, vitreous, and visual disturbances, and MEK inhibitors reported more visual disturbances with fewer inflammatory and optic nerve events. ICIs also showed higher serious outcomes and hospitalization, while BRAF and MEK inhibitors had lower reporting of serious outcomes. The strict analysis confirmed several class-specific patterns while reducing others after excluding reports with multiple agents. Conclusions Ocular adverse events associated with systemic melanoma therapies demonstrate distinct and comparatively different toxicity patterns across therapeutic classes in real-world data. By directly comparing ICIs, BRAF inhibitors, and MEK inhibitors within a unified pharmacovigilance framework, this study highlights class-specific differences in both phenotype and severity, providing a foundation for mechanism-informed monitoring strategies and multidisciplinary care.

    2026
    引用
    AI阅读
    加入学术空间
    2Goserelin-triggered Immune-Mediated Rhabdomyolysis in a Patient Receiving Long-Term Rosuvastatin Therapy: A Case Report
    Khashayar Shahverdi, Mahshad Ghoddusi, Zahra Shafizadeh, Fatemeh Afra

    Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase to reduce cholesterol but can cause muscle-related side effects. A rare severe form, immune-mediated necrotizing myopathy (IMNM), is an autoimmune condition characterized by proximal weakness, very high creatine kinase (CK) levels, and muscle necrosis with minimal inflammation. We report a 73-year-old man on long-term rosuvastatin who developed acute proximal muscle weakness, dark urine, and acute kidney injury (AKI) shortly after receiving goserelin. Laboratory tests showed severe rhabdomyolysis with markedly elevated CK and renal failure requiring hemodialysis. Muscle biopsy and serology confirmed anti-HMG-CoA reductase (anti-HMGCR) IMNM with complement-mediated muscle injury. Treatment with high-dose corticosteroids led to gradual improvement in strength, although residual renal impairment persisted at discharge. We describe a rare presentation of anti-HMGCR IMNM with fulminant rhabdomyolysis temporally associated with initiation of goserelin in a patient on chronic rosuvastatin therapy. The findings raise the possibility that gonadotropin-releasing hormone (GnRH) agonists may act as additional immunomodulatory triggers in genetically or immunologically predisposed individuals. Early recognition and prompt immunosuppressive treatment are essential to prevent irreversible organ damage and improve outcomes.

    2026
    引用
    AI阅读
    加入学术空间
    3Medication Knowledge in Psychiatric Day Hospital Patients: the Role of Polypharmacy
    Lina Sophia Queck,Johannes Heck,Olaf Krause,Martin Klietz, Franziska Kümpers, Ricarda-Katharina Vagi,Adrian Groh,Martin Schulze Westhoff,Sebastian Schröder

    Background Adequate medication knowledge of patients is critical for medication safety, particularly among psychiatric patients exposed to complex pharmacotherapy. However, data on patients treated in psychiatric day hospital settings are limited. Objectives This study aimed to assess medication knowledge and identify factors associated with knowledge gaps in this population. Design Cross-sectional observational study. Methods A total of 101 patients from a psychiatric day hospital were included. Medication knowledge was assessed using a structured interviewer-administered questionnaire covering drug name, indication, dosage and administration schedule (possible score range: 0–6). Group differences and associations were analysed using Mann–Whitney U tests, Kruskal–Wallis tests and Spearman correlations. Results The median medication knowledge score was 4.3 (interquartile range (IQR) 3.0–5.8). A moderate negative correlation was observed between the number of medications taken and knowledge (ρ = −0.404, p < 0.001). Knowledge was not associated with sex (p = 0.29) or age (ρ = −0.093, p = 0.353). Knowledge differed significantly across drug classes (p < 0.001), being highest for nervous system drugs. Discrepancies between prescribed and reported medication were frequent, with 29 patients reporting 44 additional undocumented medications. The internet (31.7%) and medical specialists (30.7%) were the most reported sources of medication-related information. Conclusion Medication knowledge among psychiatric day hospital patients varied considerably and was lower among patients receiving a higher number of medications. Frequent discrepancies between documented and patient-reported medication use were observed, indicating a potential risk for unsafe medication use. In addition, insufficient medication knowledge may represent a clinically relevant risk factor for medication-related problems. Targeted, patient-centred education strategies should be prioritized to improve medication safety in this setting.

    2026
    引用
    AI阅读
    加入学术空间
    4Specialist Teleconsultation and Changes in Potentially Inappropriate Medication Regimens among Older Adults in Primary Care: the AMELIORATION Retrospective Cohort Study
    Tarso Augusto Duenhas Accorsi, Juan Manuel Sao Bento Batista, Carlos Francisco da Silva, Flavia Oliveira Rodrigues,Anderson Aires Eduardo,Flavio Tocci Moreira,Karen Francine Kohler,Carlos Henrique Sartorato Pedrotti

    Background Potentially inappropriate medication (PIM) prescribing in older adults contributes to adverse drug events and healthcare utilization. Synchronous specialist teleconsultation may expand access to medication review, but its association with prescribing appropriateness across multiple specialties remains uncertain. Objectives To assess changes in documented and specialist-recommended PIM regimens immediately following specialist teleconsultation. Design Retrospective, paired pre-post observational cohort study. Methods We analyzed 14,995 completed teleconsultation encounters involving 13,580 unique adults aged 60 years or older in the Brazilian TeleAMES program from March 2020 through February 2025. Each encounter contributed a medication regimen documented by the primary care clinician before consultation and a regimen recommended by the specialist after consultation. PIMs were classified according to the 2023 American Geriatrics Society (AGS) Beers Criteria. The primary outcome was the encounter-level proportion with at least one PIM. Paired binary comparisons and generalized estimating equation (GEE) models with patient-level clustering were used. Regression models included time (before versus after) as the sole predictor and were not adjusted for baseline covariates. Results The proportion of encounters with at least one PIM decreased from 32.7% to 29.6%, an absolute reduction of 3.1 percentage points and a relative reduction of 9.5% (p = 0.03). The mean PIM count also decreased (incidence rate ratio [IRR], 0.971; 95% confidence interval [CI], 0.952-0.991; p = 0.004). Count rates declined for drug-disease contraindications (IRR, 0.631; 95% CI, 0.601-0.663; p < 0.001), high-risk drug-drug interactions (IRR, 0.766; 95% CI, 0.672-0.873; p < 0.001), and medications requiring renal dose adjustment (IRR, 0.929; 95% CI, 0.901-0.958; p < 0.001). The largest specialty-specific absolute reductions were observed in Cardiology (34.2% to 21.4%) and Endocrinology (38.1% to 22.3%). Conclusion Immediately after specialist teleconsultation, specialist-recommended regimens contained fewer PIMs, particularly within high-risk prescribing domains. Because post-consultation lists represented recommendations rather than confirmed dispensing, implementation, or medication use, and because no concurrent control group was available, these findings indicate an association with documented prescribing changes rather than a causal reduction in medication exposure.

    2026
    引用
    AI阅读
    加入学术空间
    5Using a Control Plan for Artificial Intelligence and Machine Learning Monitoring Within Pharmacovigilance
    Michael Glaser, Rory Littlebury,Vijay Kara

    The ethical and risk-based implementation and monitoring of artificial intelligence (AI) and machine learning within pharmacovigilance systems presents significant challenges, made more complicated by evolving regulatory landscapes. A pharmacovigilance organization requires a robust governance framework for ensuring patient safety and maintaining regulatory compliance as technology rapidly advances. This perspective review proposes a control plan as a structured, living document solution for effectively governing AI models, including statistical based machine learning, large language models, and generative AI. It integrates existing principles and requirements by suggesting critical elements such as performance parameters for the model and its infrastructure, criteria for successful human monitoring, triggers for model modification, identified risks with mitigation strategies, and appropriate explainability of AI outcomes. The objective of a control plan is to ensure transparency to regulators, safeguard patient safety, and build confidence in the organization’s risk-based management approach. The proposed AI control plan provides a structured approach to governing and monitoring AI systems within pharmacovigilance, enhancing operational transparency and regulatory compliance. It consolidates various established best practices and regulatory considerations into a unified framework. The adaptive nature of a control plan is crucial for responsible and effective AI utilization as technology and regulations evolve.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 624 篇论文

    高被引作者

    作者引用发文
    Lars Bjerrum28071
    Paul J. Gallagher5283
    Riccardo Polosa4831
    Konstantinos Farsalinos4831
    Amanda Lavan4232
    Phyo Kyaw Myint41210
    Danielle R Fixen3196
    Mina Khezrian3122
    Sunny Linnebur3106
    Tjeerd Van Staa2991

    高产作者

    作者引用发文
    Phyo Kyaw Myint41210
    Roy L. Soiza22910
    Arduino Mangoni1268
    Jules C Hancox897
    Thomas M Polasek2647
    Sunny Linnebur3106
    Danielle R Fixen3196
    Bell J Simon415
    Richard Woodman575
    Andrew Bate855

    相关期刊

    Drug Target Insights
    European Journal of Clinical Pharmacology
    Clinical drug investigation
    International Journal of Clinical Pharmacy
    European journal of hospital pharmacy : science and practice
    Drugs - real world outcomes
    Journal of pharmaceutical health care and sciences
    Therapie
    Farmacia Hospitalaria
    Journal of managed care & specialty pharmacy